IL6 and congenital rubella syndrome: Initially treated supportively, management of ICANS currently includes corticosteroids, tocilizumab (if co-occurring with CRS, although there are concerns about enhancing IL-6 levels in the CSF due to non-CSF permeability of tocilizumab) and, if refractory, anakinra, intrathecal chemotherapy, and CSF pressure relief (109–111).